|
|
6 Blackstone Valley Place Suite 500
Lincoln, RI 02865
phone:+1 401 333 3880
fax:+1 401 333 3881
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.neurotech.fr
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Sight-Saving Therapies for Chronic Retinal Diseases |
|
| Management |
| Mr. Ted Danse, President and CEO; Weng Tao, M.D., Ph.D., Chief Scientific Officer, Vice President, Research & Development, USA; Mr. William E. Tente, Vice President, Operations, USA; Bryant E. Fong, Burrill and Company; William J. Link, Ph.D., Versant Ventures; Laurent Ganem, M.D., MBA, APAX Partners; Lutz Giebel, Ph.D., SV Life Sciences |
| |
|
|
| |
|
| Keywords |
| drug delivery, cells, retinitis pigmentosa, retina, eye, diseases, pharmaceuticals, DrugDelivery |
|
|
|
| Description |
|
Neurotech is a privately held biotechnology company developing sight-saving therapeutics for chronic retinal diseases, including indications that address significant unmet medical needs and that, as a whole, represent the largest market opportunity in ophthalmology. |
|
| Products / Services |
Neurotech's lead product consists of encapsulated cells genetically modified to secrete CNTF, a neurotrophic factor exclusively licensed from Amgen. This product is initially being developed for the treatment of retinitis pigmentosa in the eye with the intent of expanding the indication later to include other forms of visual degeneration.
|
|
| Technology / Differentiation |
| Neurotech's patented core technology platform, Encapsulated Cell Technology (ECT) enables the controlled, continuous delivery of proprietary therapeutic factors directly to the retina, bypassing the blood-retinal barrier and overcoming a major obstacle in the treatment of retinal diseases. Conventional approaches to therapy are limited by the absence of an acceptable means of sustained protein delivery across the blood-retinal barrier. While therapeutic agents can be injected directly into the eye, this is an impractical approach if regular administration is required. Neurotech's ECT implants are semi-permeable, hollow fiber membranes that encapsulate genetically modified cells that produce a specific therapeutic protein. Long-term protein delivery (up to 18 months) to the back of the eye and retina has consistently been demonstrated with ECT devices in preclinical studies and recent clinical results continue to support the long-term cell viability of ECT. |
|
|
| Funding |
| 3I Group plc, GIMV, Atlas Venture, West LB, Avida Equity Partners, CDC Entreprises Innovation, Sofinnova Partners, Banexi Venture, Alpha Associates, Sudinnova, AGF Innovation, Edmond de Rothschild Investment Partners, XAnge Private Equity, Banque de Vizille, Siparex. |
|
| Status |
| The company's lead product candidate for GA and RP is in late-stage clinical development; clinical trials for additional products and indications (i.e., wet AMD) are expected to commence in late 2009. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members